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Abstract
Liver transplantation (LT) is a common current technique for end-stage liver 
disease. Complications after the surgical procedure, though uncommon, can be of 
very different origin and can also be severe enough to lead to liver and multiorgan 
failure and finally graft loss and/or recipient’s death. Intensivists and the surgical 
team must be familiarized with these early complications to detect them as soon 
as possible in order to use the best diagnostic tools and take the best therapeutic 
measures to restore anatomical integrity and organ function to optimize the liver 
graft. In this chapter, we present an updated state of the art for efficiently tackling 
with all different, most usual complications that an LT patient can present during 
early postoperative period.
Keywords: liver transplantation, liver graft dysfunction, liver posttransplant 
complications, liver function monitoring, posttransplant critical care
1. Introduction
Liver transplantation (LT) is the only therapy for end-stage liver disease. It has 
become a common surgical procedure. The postoperative severe complications may 
compromise both patient’s graft and life survival, so an early suspicion, detection, 
and therapeutic solution are the only way to change the threatening of post-LT 
complications.
The need of allografts has largely extended the set of criteria (ECD) for organ 
acceptability, increasing the risk of complications and adverse outcomes [1, 2].
Little is known about the parameters that can alert of early complications of liver 
graft function, need of retransplantation, vascular complications, reinterventions, 
and long intensive care stay.
Hereby we present the state of the art on the early detection and management of 
the most frequently complications found during the postoperative period of liver 
transplantation in the intensive care unit (ICU). We discuss the management of clini-
cal, laboratory, and ancillary tests’ findings that can help medical and surgical staff to 
tackle and take decisions when suspecting early hepatic graft malfunctioning. Early 
diagnosis could allow medical and surgical teams to take most difficult decisions to 
salvage the graft and to restore severe deteriorated patient’s health condition.
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Laboratory tests as well as scores (model for end-stage liver disease, MELD; 
acute physiology and chronic health evaluation, APACHE II; sequential organ 
failure assessment, SOFA; and model of early allograft function, MEAF) have good 
performance but can only do a late evaluation of patient status and graft function. 
The indocyanine green plasma disappearance rate is an interesting liver function 
test but produces some ambiguous results during the first days after transplanta-
tion. The liver maximal function capacity test is a novel and promising method for 
evaluating metabolic liver activity, but its use is limited for economic reasons and 
extrahepatic factors.
Recently somatic near-infrared spectroscopy of liver graft (LSrO2) has shown to 
be helpful to early monitor vascular graft supply after LT [3].
2. Vascular complications of the liver graft
Vascular complications after LT though seldom found are dreaded ones, as they 
carry high incidence of both loss of the graft and patient morbimortality [1].
Complications that affect the hepatic artery (HA) after LT can lead to ischemia 
of the liver graft which can result in graft morbidity, loss, or even patient death. The 
clinical feature of these complications varies and depends on the type (thrombosis 
or stenosis) and timing (early or late presentation) and the promptness of diagnosis 
[4–10]. Despite continuous improvements of the surgical technique, these com-
plications represent one of the main causes of the failure of LT, with an incidence 
ranging from 2.6 to 20% in adult recipients [4–10].
2.1 Early monitoring of vascular graft supply and vascular complications
As it is hard to establish an effective screening of the risk of each patient under-
going LT, it is of paramount importance to bear in mind the possibility of early 
appearance as most studies and clinical experience have failed to demonstrate clear 
risk factors [4–12].
At the ICU it is difficult to monitor early graft vascular supply. Duplex ultra-
sound (DUS) is the usual tool used for this purpose, but it only provides informa-
tion at a given point of time of the study but no continuous information.
Adequate perfusion and oxygenation to liver graft after transplantation are 
essential for its viability. LSrO2 through near-infrared spectroscopy (NIRS) can 
help by showing real-time oxygen content of the graft. Recently, our group carried 
out a study on post-LT patients for evaluating the efficacy of NIRS on detecting 
early vascular graft complications [12, 13]. Impairment of the liver graft microcir-
culation and tissue hypoxia are both a common pathology in all these complications 
with eventual loss of the graft without early intervention [14]. Early detection of 
this impairment could reduce the overall morbidity and mortality of LT by allow-
ing earlier treatment. Measurement of hepatic LSrO2 has been shown to correlate 
significantly with the microcirculatory impairment and liver dysfunction induced 
by ischemia and reperfusion injury [12, 15].
The mean initial value of LSrO2 that our group observed was 74 (SD 5.7) 
with a tendency of a slight progressively increment along the following hours, 
showing a mean value of 76 (SD 4.1) at hour 24. When studying correlation 
of LSrO2, relevant and significant findings at hour 3 were found between this 
parameter and hemoglobin (Hb) (p = .004), as well as with cardiac index (CI) 
(p = .044). It was also found with the Apache II scale (p = .041) but not with 
SOFA (p = .069).
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At hour 24, we also found significant correlation between LSrO2 and Hb 
(p = .002). No correlation was met with lactate at any moment (hour 1, hour 8, and 
hour 24) of the study (p = .113, p = .293, and p = .141, respectively).
Importantly, neither at the beginning nor at the end of the study was there a 
correlation observed between LSrO2 and liver biochemistry.
Finally, among hemodynamic parameters, a correlation was encountered 
between LSrO2 and CI at hour 3 (p = .044). DUS data expressed as resistive index 
and pulsatility index (RI and PI) did not correlate with LSrO2 at hour 24 (p = .738 
and p = .799, respectively). We could not also find any statistical connection 
between LSrO2 and cold-warm ischemia time and at arrival after 24 hours (p = .780 
and p = .951).
LSrO2 could early detect all severe vascular complications and all events that 
led to a decrease in blood or oxygenation supply to the liver graft, permitting to 
advance in taking diagnostic and therapeutic measures.
LSrO2 is a new monitoring tool that brings valuable information about hepatic 
flow and oxygenation early after liver transplant that deserves to be weighed.
2.1.1 Arterial complications
2.1.1.1 HAT
Hepatic artery thrombosis (HAT) [16] differs depending on time of presenta-
tion, usually ranging from 1 to 28 days (mean 7.4 days) [4].
HAT represents the most common vascular complication, accounting for 
more than 50% of all vascular complications [13]. Late reports show a lower HAT 
incidence, ranging from 1 to 25% [13, 17, 18]. It is the first cause of non-function of 
the graft [13].
The clinical presentation of HAT ranges from a mild elevation of liver function 
tests (LFT) and bilirubin levels in 75% of patients to fulminant hepatic necrosis. 
Other symptoms vary from biliary complications in 15%, fever and sepsis in 6%, 
and graft dysfunction or failure in 4% [13]. The clinical expression depends on the 
timing and the existence of collaterals. Early HAT is mostly expressed as a non-
functioning graft, and late HAT is associated with biliary tract complications (bile 
duct strictures and/or biliary leaks).
Early HAT usually is manifested with fever, increased leukocytosis, and 
important elevation in liver enzyme levels. The natural history of early HAT can 
be summarized as biliary tract necrosis followed by uncontrolled septic shock in 
the immunosuppressed population and even the patient’s death [6, 13, 19–22]. The 
cause of early HAT is still under debate and remains unknown [6, 19, 21–23]. Up to 
20% of HAT cases are due to surgical causes [6, 19, 21–23].
Early diagnosis is mandatory to allow immediate treatment. Elevation of transami-
nase levels, LSrO2 monitoring [3] showing a > 10% reduction from basal data, duplex 
ultrasound (DUS will show absence of HA signal sensibility of 92%) and increased 
resistive index (RI). Visceral angiography will confirm the diagnosis [19, 22, 24].
Approximately 20% of them can be treated successfully with surgical revas-
cularization with a Fogarty balloon-tip catheter and refashioning of the arterial 
anastomosis the very same day of diagnosis [4]. Percutaneous endovascular 
interventions including intra-arterial thrombolysis (IAT), percutaneous translu-
minal angioplasty (PTA), and stent placement have shown hopeful outcomes in 
the literature [13]. Anticoagulant or antiplatelet therapy is also advisable [13, 16]. 
Survival rates are 40% in symptomatic vs. 82% in asymptomatic patients [13]. Sylva 
et al. reported an overall mortality of 23% [20].
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Different factors that cannot be involved in the appearance of HAT are etiology 
of recipient end-stage liver disease, previous LT, donor sex and age, cause of donor 
death, recipient sex and age, type of preservation solution, cold ischemia time, 
experience of the surgeon, type of arterial anastomosis, intraoperative transfusion 
requirement of red blood cells and fresh frozen plasma, acute rejection, and CMV 
infection. Donor age of greater than 60 years and back-table artery reconstruction 
have been found significantly associated with this complication [4].
2.1.1.2 HAS
Hepatic artery stenosis (HAS) is not rarely found and its incidence ranges 2–13% 
[13, 16]. It is defined as a narrowing of the transverse diameter of the HA, resulting 
in ischemia mainly revealed by elevated liver function tests [13, 25–31]. Significant 
HAS is defined as a reduction of >50% on angiogram associated with a resistive 
index (RI) <0.5 and a peak systolic velocity >400 cm/s by Duplex ultrasound (DUS) 
[8, 13, 26, 32]. LSrO2 reduction of >10% from basal levels and maintained dur-
ing first hours can alert of HAC [3]. HAS also carries a high rate in morbidity and 
mortality. It has been postulated that HAT and HAS are two contiguous components 
of the broader allotransplant ischemic complications [13, 25–28, 30–35].
2.1.1.3 HAP
Hepatic artery pseudoaneurysm (HAP) is defined as a dilated hepatic artery, 
which occurs after iatrogenic injury in most cases, causing blood leaking and pool 
outside the artery wall into surrounding tissue with a persistent communication 
between the HA and the adjacent cavity [13].
Volpin et al. [36] informed of an incidence of 2.5% and Boleslawski et al. of 
0.64% [37].
The clinical presentation varies from an asymptomatic state to an incidental find-
ing upon abdominal pain associated with fever and gastrointestinal bleeding (25%), 
massive bleeding through abdominal drain (31%), and hemorrhagic shock (81%).
Several predisposing factors have been suggested, including peritoneal infec-
tions, technical difficulties during anastomosis, and biliary leak [24, 27, 35–62]. The 
rate of microorganisms cultured from HAP is 50% and from abdominal fluid 31% 
[36]. Diagnosis of HAP is based on DUS, contrast-enhanced CT scan, or angiog-
raphy [36]. Treatment is based on reoperation or interventional radiology [36, 37, 
42, 45, 63]. Urgent ligation of HA has a mortality that ranges from 28 to 85% [36, 
40, 41, 45]. Boleslawski et al. [37] reported good results with HA ligation without 
revascularization.
2.1.1.4 HAR
HAR is defined as a severe hemorrhage from the trunk or from the main branch 
of the HA. It is a very serious complication that results in the disruption of blood 
supply to the graft. This is an exceptional but dramatic complication that carries a 
very high rate incidence of graft loss and mortality.
In most cases, this condition complicates a pseudoaneurysm of the HA, leading 
to major bleeding that requires emergency operation. Many authors report the role 
of infectious pathogens as causative agents of pseudoaneurysms [13]. Diagnosis of 
HAP is available with different radiological techniques, but in half of cases, HAP is 
not recognized before rupture, requiring immediate surgery [37].
In case of rupture and acute bleeding, there are many therapeutic possibilities: 
endovascular intervention with embolization with or without stenting, surgical 
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intervention for anastomotic revision, aorto-hepatic grafting, HA ligation, or 
emergency retransplantation. Mortality remains very high, and no consensus exists 
about indication for the type of procedure [13, 37, 40, 45, 47, 64].
Boleslawski et al. [37] reported the largest series of ruptured posttransplant 
HAP and highlighted the efficacy of primary HA ligation with good (70–80%) early 
and late survival.
2.1.2 Venous complications
Compared to arterial complications, venous complications (VC) are less fre-
quent, with an estimated overall incidence of <3% [65–72]. They can be potentially 
devastating, leading to graft failure and representing an important source of mor-
bidity and mortality, especially if they occur in early period of post-LT [68, 71, 72].
Incidence is higher in pediatric population [68, 69, 73, 74].
The etiology of VC mostly involves venous anastomosis; those are portal, cava, 
and hepatic veins.
Portal vein complications (PVCs) are relative uncommon, occurring in 1–3% 
of LT [65–68, 70–72, 75]. These complications are related to high morbidity and 
graft loss [67, 68]. These complications are more common with split liver and living 
donor LT and in pediatric LT [72, 76].
Regarding PVCs we can make the diagnosis by DUS, contrast-enhanced ultra-
sound (CEUS), contrast-enhanced computed tomography (CECT), and magnetic 
resonance venography (MRV) [67, 68, 77]. Therapeutic management of PVCs 
ranges from endovascular procedures (as the first-line treatment) with highly suc-
cessful results [50, 69, 74, 78] to surgical thrombectomy and anastomosis revision.
2.1.2.1 Portal vein thrombosis (PVT)
Incidence ranges from 0.3 to 2.6% [51, 71]. The clinical presentation depends on 
the time of thrombosis. Early thrombosis (<72 h) is presented as acute liver insuf-
ficiency or graft failure. If PVT occurs late (>day 30), clinical symptoms depend on 
the portocaval collateral circulation existence. Portal hypertension manifestations 
including upper gastrointestinal bleeding due to esophagogastric varices and ascites 
are the most frequent symptoms, and liver failure is rare [35, 71, 75]. PVC usually 
occurs during the first week after LT [27, 35, 52, 79]. The most common causes of 
PVT are technical errors related to venous redundancy, kinking, or stenosis of the 
anastomosis [71].
Therapeutic options for PVT range from systemic anticoagulation, catheter-based 
thrombolytic therapy via transjugular intrahepatic portosystemic shunt (TIPS), 
to surgical revision until retransplantation. The best three percutaneous options 
in literature are transhepatic vein angioplasty (with or without stent placement), 
percutaneous thrombolytic treatment via TIPS, and transsplenic approach [53, 54].
In clinical practice, the treatment depends on timing of appearance, if early liver 
failure or multiorgan failure appear, it compels surgical revision and if PVT is late to 
occur and no alteration in liver function test, observation, or medical treatment and 
complementary percutaneous treatment is required. If PVT is late in developing 
and with clinical manifestation of acute gastroesophageal bleeding or ascites, that 
will require percutaneous or TIPS procedures [55].
2.1.2.2 PVS
The true incidence of portal vein stenosis (PVS) is not known. The only data in 
literature concerning the incidence of venous complications is <3% [72].
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When PVS is diagnosed, it can be present with acute graft failure or portal hyperten-
sion [56]. In practice the vast majority of patients are asymptomatic, and the finding is 
incidental on routine scanning ultrasound. In the case of symptomatic PVS, clinical signs 
will be those of portal hypertension as gastrointestinal bleeding due to gastroesophageal 
varices, ascites, and splenomegaly. Abnormal liver function tests are not constant.
Risk factor for developing PVS is the same as for PVT. The significant size 
mismatch is likely a cause of developing a stenosis [72].
DUS is the first tool for PVS diagnosis; it is highly sensitive but not specific. 
Some authors as Wei et al. [57] consider a pre- and post-stenosis gradient of >5 as 
compatible with PVS. Other authors prefer to rely on portal caliper diameter, and a 
reduction of >75% is suggestive [58].
In case there are no important clinical signs, the patient may be solely observed. 
If clinical picture is progressively deteriorating, a therapeutic access as transhepatic 
approach or transjugular access [58] must be done. A single balloon dilatation is 
sufficient to maintain patency in 77.7% of patients. In selected cases, a stent can be 
placed to prevent recurrence [59]. The use of three anticoagulant therapies (low-
molecular-weight heparin, warfarin, and aspirin) may reduce the recurrence of 
thrombosis [60].
2.1.2.3 CVC
Caval vein complications (CVC) are extremely infrequent. They can be due to 
kinking, stenosis, or thrombosis and clinically appear as lower limb edema, ascites, 
pleural effusion, Budd-Chiari syndrome, and liver or renal failure [61, 65, 70].
Technical errors are the leading cause of CVC. Diagnosis should be made by 
DUS, contrast-enhanced CT, or cavography. Percutaneous radiological interven-
tions are the methods of choice for therapeutical approach [59, 62, 80–83].
3. Biliary complications after liver transplantation
The most frequent and important causes of morbidity and mortality in LT recipi-
ents are stenosis, biliary leaks, and stones. The estimated incidence is 10–25% [84]. 
Most can be managed successfully with endoscopic retrograde cholangiography (ERC).
3.1 Types of complications
Biliary complications (stenosis, leaks, and stones) after LT can be classified as 
early (within 4 weeks) or late. Biliary strictures can be further divided into intrahe-
patic anastomotic stenoses, not anastomotic and diffuse stenoses. Other complica-
tions, such as bile emptying, Oddi sphincter dysfunction, mucocele, and hemobilia, 
are rare (Table 1).
3.2 Risk factors
There are several risk factors for development of biliary complications after LT 
(Table 2):
• Type of biliary reconstruction: ductal choledochocholedochostomy versus 
choledochojejunostomy in Roux-en-Y; the complication rate is similar [85].
• Routine tube placement in T: it is associated with a higher incidence of biliary 
complications, such as stenosis, biliary leaks, and cholangitis [86].
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• Other risk factors (especially stenosis): acute thrombosis of the hepatic artery, 
stenosis of the hepatic artery, biliary leak, technical factors during surgery 
(excessive dissection of the periductal tissue during acquisition, excessive use 
of electrocautery for the control of bile duct bleeding) both in the donor and 
the recipient, the tension of the anastomosis, small caliber of the bile duct 
and the size of the donor and recipient not matching, ischemia injury/reper-
fusion, pre-LT diagnosis of cytomegalovirus infection, donation after cardiac 
death, ABO blood mismatch in the group, increased donor age, prolonged 
periods of cold and warm ischemia, and primary sclerosing cholangitis 
(Table 2) [85].
3.3 Diagnostic approach
In asymptomatic LT recipients that have elevations in serum levels of amino-
transferases, bilirubin, alkaline phosphatase, and/or gamma-glutamyl transferase. 
Occasionally, they have nonspecific symptoms (fever and anorexia), abdominal 
Table 1. 
Biliary complications after liver transplantation.
Table 2. 
Risk factors for the development of biliary complications after liver transplantation.
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pain in the right upper quadrant (especially with biliary leaks), pruritus, jaundice, 
and biliary ascites. However, pain may be absent due to immunosuppression and 
hepatic denervation [85].
The initial evaluation should include hepatic ultrasound (US) with Doppler of 
the hepatic vessels (Figure 1). If US Doppler suspects stenosis or occlusion of the 
hepatic artery, a computed tomographic (CT) angiogram should be obtained or a 
liver angiogram should be performed.
Liver biopsy is performed to exclude rejection, although it is usually deferred in 
patients with bile dilation and/or the presence of stones in the common bile duct 
due to the risk of causing a bile leak [87].
The abdominal US may not be sensitive enough (sensitivity 38–66%) to detect 
biliary obstruction [88]. Therefore, an additional evaluation with more sensitive 
techniques is recommended in patients with clinical suspicion.
If there is a strong clinical suspicion and US that indicates an obstruction of the 
bile duct with or without stones or a bile leak, cholangiography should be obtained 
[85]. Although ERC or percutaneous transhepatic cholangiography (PTC) remains 
the gold standard, magnetic resonance cholangiopancreatography (MRCP) is a 
reliable technique (96% sensitivity and 94% specificity) [89]. Currently, MRCP 
is considered an optimal noninvasive diagnostic tool for the evaluation of biliary 
complications after TL, if the abdominal US is normal and there is a high suspicion 
of a biliary complication [89].
ERC is perhaps the best diagnostic/therapeutic intervention in patients with 
conduit-to-conduit anastomosis. We reserved PTC for patients in whom ERC was 
not successful and in patients with Roux-en-Y choledochojejunostomy [90].
3.4 Stenosis
The incidence ranges from 4 to 16% [85]. Stenoses that occur early after TL are 
due to technical problems, while late stenoses are due to vascular insufficiency and 
scarring and fibrosis problems. Bile leakage is an independent risk factor for the 
development of anastomotic stenoses. Stenoses were more common with recon-
struction with Roux-en-Y choledochojejunostomy.
They are classified as anastomotic or non-anastomotic, according to the place.
3.4.1 Anastomotic stenosis (AS)
It occurs within the first 12 months after LT. It has a good response to short-term 
stenting (3–6 months). However, patients require long-term surveillance, since the 
restrictions are often repeated.
The cholangiographic appearance characteristic of an AS is that of a narrowing 
of the area of the biliary anastomosis. In some patients, it may manifest itself in 
the first or second month after TL due to postoperative edema and inflammation 
[85]. This type responds to endoscopic balloon dilation and placement of the plastic 
stent; in most patients, it will be resolved in 3 months. The majority of patients with 
AS require continuous ERC (every 3 months) with balloon dilation and long-term 
stenting (12–24 months). Due to the high success rates, we suggest that endoscopic 
management be considered.
There is growing experience in the temporary placement (3–12 months) of 
self-expanding metal stents (cSEMS) covered to reduce the need for repeated 
stent exchanges [91]. There is insufficient data to support the systematic use, but 
the cSEMS may be beneficial in patients who fail therapy with plastic stents and 
dilatation [91].
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In 4–17% of cases, ERC cannot be performed successfully because the AS could 
not be crossed with a guidewire. Previous leaks of bile and high blood transfusion 
requirements during surgery are risk factors for the initial failure of ERC. The 
majority of these patients will require surgery. In patients with Roux-en-Y choledo-
chojejunostomy, ERC is often unsuccessful, and we suggest treatment with PTC 
and dilation, followed by placement of a percutaneous transhepatic catheter [92]. 
Surgical revision (usually a repair or conversion to a Roux-en-Y choledochojejunos-
tomy) may be an alternative in stable patients with a duct-to-duct stenosis that is 
difficult to treat.
3.4.2 Non-anastomotic stenoses (NAS)
These are mainly due to thrombosis of the hepatic artery or other forms of isch-
emia. Less commonly, they may be due to the recurrence of the underlying disease, 
such as primary sclerosing cholangitis. Its incidence is 0.5–10%.
NAS can occur proximal to the anastomosis in the extrahepatic or intrahepatic 
bile duct. There may be multiple stenoses that affect the hilum and intrahepatic 
ducts, causing a cholangiographic appearance that resembles primary sclerosing 
cholangitis. Bile sludge can accumulate proximal to the stenosis, leading to recur-
rent episodes of cholangitis.
NAS are more difficult to treat than AS. NAS endoscopic therapy consists of a 
balloon dilatation followed by sphincterotomy and plastic stents with replacement 
every 3 months. NAS results are not as favorable as AS. Only 50% have a long-term 
Figure 1. 
Algorithm for the diagnosis and evaluation of suspected biliary obstruction after liver transplantation.
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response with endoscopic therapy with dilatation and stent placement. In addition, 
up to 50% undergo a transplant or die [93]. As a general rule, ischemic events that 
lead to diffuse stenosis of the intrahepatic bile duct are associated with poor graft 
survival.
Surgical revision may finally be necessary in strictures that are refractory to 
endoscopic or percutaneous treatment. A Roux-en-Y choledochojejunostomy is 
performed in patients with conduit-to-conduit anastomoses. In those who already 
have a Roux-en-Y anastomosis, it may be necessary to reposition the bile duct of the 
graft in a better vascularized area.
3.5 Biliary leaks
They have an incidence between 2 and 25%. The presence of a bile leak is an 
independent risk factor for the development of early or late stenoses. Leakage of the 
anastomosis, the cystic duct, the T-tube tract, or (in living donor or an LH divided 
into the liver) the cut surface of the liver may occur. Biliary leaks can be divided into 
early and late.
3.5.1 Early bile leaks
They occur at the site of the anastomosis and are often related to technical 
problems. Predisposing factors include the lack of perfusion of the hepatic artery 
and other technical reasons. They must be suspected in case of peritonitis or fluid 
collections in imaging tests.
In cases where a T-tube is placed, small anastomotic leaks can be diagnosed with 
a T-tube cholangiogram and can be controlled by leaving the tube open. In patients 
without a T-tube, ERC is the standard diagnostic method. Hepatobiliary scintigra-
phy (HIDA) can be useful in cases where there is a low suspicion of leakage [94].
The placement of a plastic stent, with or without biliary sphincterotomy, is 
successful in 90 to 95%. As a result, ERC is the treatment of choice. In some cases, 
small leaks can be treated with biliary sphincterotomy alone. The stent remains 
2 months and is not changed during this period unless there is a clinical suspicion of 
obstruction.
Anastomotic leaks from Roux-en-Y choledochojejunostomy are less common. It 
can be diagnosed with a HIDA scan if the patient does not have a drainage catheter 
in place. ERC is often not feasible due to anatomical difficulties. Management is 
usually performed with internal-external percutaneous drainage and more fre-
quently requires surgical treatment.
3.5.2 Late leaks of bile
They are usually related to the removal of the tube in T. It should be suspected in 
patients who develop pain when the tube is removed in T. ERC is indicated (with or 
without sphincterotomy) with transpapillary stenting [95]. Surgery or a percutane-
ous transhepatic approach is reserved for patients in whom the endoscopic approach 
is unsuccessful. Some centers use nasobiliary tubes instead of stents.
3.6 Biloma
They are produced by rupture of the duct and extravasation of bile in the 
hepatic parenchyma or abdominal cavity, in patients with necrosis of the bile duct 
secondary to thrombosis of the hepatic artery. Most post-LT bilomas occur in the 
perihepatic area, outside the liver. If the biloma occurs in the hepatic parenchyma 
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and communicates with the biliary tree, it may resolve spontaneously or, in some 
cases, be treated with endoscopy and a transpapillary stent. Large bilomas that do 
not communicate with the bile ducts should be treated with percutaneous drainage 
and antibiotics. Surgery is indicated when it cannot be effectively controlled with 
nonsurgical methods.
3.7 Filling defects of the common bile duct
They can be due to gallstones, sludges, blood clots, cylinders, and/or migrated 
stents [88]. Gallstones, cylinders, and sludge are relatively common after TL, with 
an incidence between 2.5 and 12%. The related mechanisms are stenosis, warm and 
cold ischemia, bacterial infection, and obstruction [95].
3.7.1 Stones
They appear late after the TL. In the majority of cases (59–66%), a session of 
ERC with biliary sphincterotomy was sufficient for cleaning the canal.
3.7.2 Molds
They are seen more frequently in the context of ischemia (e.g., thrombosis of 
the hepatic artery), when there is a diffuse stenosis of the hilum [96]. Mold clean-
ing can be difficult to achieve with endoscopic methods. Combined endoscopic 
and percutaneous methods can be performed successfully [96]. Often several 
combinations of sphincterotomy, balloon and basket extraction, stent placement, 
and lithotripsy are necessary, and many patients will eventually require treatment 
with PTC. Patients with Roux-en-Y choledochojejunostomy should be treated with 
a percutaneous method.
3.8 Sphincter of Oddi dysfunction
It has been described in 2–7% [79]. The pathogenesis is not clear; one hypothesis 
is that the denervation of the common bile duct in the ampullary region (secondary 
to surgery) leads to the development of a hypertonic sphincter, which causes dilata-
tion of the ducts and cholestasis. In most studies, the diagnosis was based on clinical 
suspicion and response to biliary sphincterotomy [79].
3.9 Other complications
3.9.1 Mucocele
It is a rare complication after LT caused by an accumulation of mucus from the 
cells lining the remnant of the cystic duct, leading to extrinsic compression of the 
bile duct. Its formation is insidious and therefore difficult to diagnose. A CT scan or 
US will reveal the mucocele as an accumulation of fluid in the region of the hepatic 
portal. The diagnosis can be confirmed with MRCP [95]. Most patients will require 
surgical or radiological drainage.
3.9.2 Hemobilia
It may occur in patients undergoing percutaneous liver biopsy or percutaneous 
transhepatic cholangiography. This condition can cause transpapillary bleeding, 
along with biliary obstruction, due to the formation of clots. The treatment is 
Acute Liver Dysfunction - Principles and Practice
12
conservative but may require angiography with embolization. Biliary obstruction 
can be treated with percutaneous drainage or ERC.
3.9.3 Bactobilia
Patients who have undergone LT are predisposed to bacterial colonization of the 
bile ducts. Mechanical obstruction, plastic stents, gallstones, and sphincterotomy 
significantly increased the risk of bactobilia. The majority are asymptomatic. It 
is possible that bactobilia is a predisposing factor for the development of biliary 
complications after LT.
3.9.4 Biliary plaster syndrome
It refers to the presence of biliary cylinders and debris that cause biliary obstruc-
tion. Associated risk factors include hepatic artery stenosis and biliary stenosis [97]. 
Patients who develop biliary emptying syndrome have poor graft survival and a 
worse post-LT result than LT recipients without biliary emptying syndrome. Several 
endoscopic approaches have been described with varying success.
4. Rejection in liver transplant
4.1 Introduction
The human immune system is a host defense mechanism against the invasion 
of pathogens. However, a side effect of the ability of the host immune system to 
recognize and attack “nonself” tissues is rejection of grafted tissues posttransplan-
tation. The exogenous modulation of the host immune system to allow sustained 
graft function has proceeded along with—and often preceded—our understanding 
of the physiologic mechanism of rejection and tolerance [98, 99].
The immunologic disparity among members of the same species of mammals 
that leads to recognition of “self” tissue and to rejection of nonself tissue is based on 
the differences in cell surface molecules that are expressed. In humans, these major 
histocompatibility antigens are termed human leukocyte antigens (HLAs). HLAs 
are subdivided into two classes: class I (HLA-A, HLA-B, and HLA-C), expressed on 
the surface of all nucleated cells, and class II (HLA-DR, HLA-DQ , and HLA-DP), 
expressed on the surface of antigen-presenting cells (APCs) [98–101].
The recognition of nonself tissue occurs via two distinct immunologic pathways: 
direct and indirect allorecognition. Direct allorecognition consists of host T-helper 
cells recognizing donor HLA disparity expressed on the donor cell surface. Indirect 
allorecognition consists of recipient APCs (e.g., activated macrophages, dendritic 
cells, and B lymphocytes) phagocytosing donor cellular debris, including HLAs, 
which are then processed and re-presented on the APC surface to be recognized by 
recipient T-helper cells (CD4+ lymphocytes) (Figure 2) [100].
In either pathway, co-stimulation signals between CD4+ T-helper lymphocytes 
and CD8+ cytotoxic T lymphocytes trigger a cascade of immunologic events. 
Interleukin (IL)-2, an important and early signal in immune activation, is secreted 
by activated CD4+ T-helper lymphocytes, stimulating increased T-cell respon-
siveness, clonal expansion of alloreactive T lymphocytes, and acquisition of the 
cytolytic phenotype by host T lymphocytes. Direct allorecognition leads to a more 
immediate and vigorous immune response against foreign tissue, but, in both 
pathways, additional helper T lymphocytes are recruited and secrete a wide array of 
cytokines (e.g., IL-1, interferon-γ, tumor necrosis factor-α), facilitating the further 
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recruitment of cytotoxic T lymphocytes, natural killer cells, and B lymphocytes. 
B lymphocytes begin to secrete antibody directed against the allogeneic tissue in 
ever-increasing quantities. B lymphocytes also play an antibody-independent role in 
graft rejection through the secretion of proinflammatory cytokines and chemokines 
and the participation in antigen presentation [98–102].
Rejection mechanistically occurs by infiltration of the graft by effector cells, the 
binding of antibody, and the activation of complement. Unchecked, the phenom-
enon inexorably leads in graft loss (Table 1) [100].
Rejection is classified according to the temporal relation between the implanta-
tion of the graft and its dysfunction supported by the histologic features seen in 
allograft: hyperacute (HAR), acute (AR), and chronic (CR). Each type is mediated 
by a different host immune mechanism.
4.2 Hyperacute rejection
HAR occurs within a few minutes to a few hours after the reperfusion of the 
graft. Preformed antibodies directed against antigens presented by the graft 
mediate activation of complement activation of endothelial cells, and formation of 
microvascular thrombi, leading to graft thrombosis and loss. The process is irre-
versible and, currently, no treatment is available.
HAR is mediated by circulating preformed antibodies, normally directed against 
ABO system (comprising the four main blood types, i.e., A, B, AB, and O) antigens 
or against major HLA antigens. The screening of potential transplant recipients and 
strict adherence to ABO verification prevent nearly all HAR [101].
In pretransplantation study, crossmatch testing is performed to identify pre-
formed antibodies against class I HLAs (T-lymphocyte crossmatch testing) and 
class II HLAs (B-lymphocyte crossmatch testing). Crossmatch testing helps clini-
cians to identify the presence of antibodies against potential donor antigens and 
to assess the risks of posttransplant rejection and subsequent graft loss. However, 
these crossmatching assays are not standardized [98, 101, 102].
At most centers, heart and liver transplantations are performed without a 
crossmatch (except with system ABO compatibility between donor and recipient), 
unless the recipient is highly sensitized or has previously received a graft possessing 
major antigens in common with the current donor.
In liver transplant recipients, anti-HLA antibody-mediated HAR has been 
described, but HAR due to ABO-incompatible blood groups is seen in up to 33% 
and described as a more delayed form of antibody-mediated rejection, but even this 
barrier appears surmountable with the use of plasmapheresis along with aggressive 
immunosuppression. Unlike the renal graft, the hepatic graft can undergo HAR 
over a number of days, probably secondary to its ability to absorb a large amount of 
antibody and its functional reserve before the onset of the significant microthrom-
bosis and vascular damage [100–102].
Figure 2. 
Direct and indirect pathways of allorecognition (modified Ref. [100]).
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The diagnosis of HR in liver transplant recipients is normally suggested by fever 
and rapid deterioration in graft function: AST >1000, coagulopathy, acidosis, 
encephalopathy, and distributive shock. The differential diagnosis may be that of 
primary non-function/delayed function and hepatic artery thrombosis [101].
The histological features of hyperacute rejection are vascular congestion, fibrin-
platelet thrombi within capillaries, neutrophilic vasculitis with fibrinoid necrosis, 
prominent interstitial edema, and neutrophil infiltrates [98, 100].
In unsuccessful cases the only treatment is retransplantation.
4.3 Acute rejection
AR is the most common form of graft rejection. It may develop at any time 
but is most frequent during the first several months posttransplant. Rarely, it 
occurs within the first several days posttransplant, a process termed accelerated 
acute rejection, most likely a combination of amnestic immune response driven 
by sensitized memory B lymphocytes and activation of the direct allorecognition 
pathway [99].
AR may be cell mediated, antibody mediated (AMR), or very occasionally 
mixed. Histologically, AR generates an infiltration of activated T lymphocytes into 
the graft, resulting in gradually progressive endothelial damage, microvascular 
thrombosis, and parenchymal necrosis. Pathologic grading schemes have been 
developed regarding the extent to which AR involves vascular damage, cellular 
infiltration, or a combination of both [98, 99, 101].
Without intervention, AR inevitably progresses to graft loss. The clinical 
presentation of AR varies markedly, depending on the specific organ, on the level 
of immunosuppression, and on the attendant level of inflammation in the affected 
tissues.
Unless the host immune system is adequately suppressed pharmacologically, 
transplantation inevitably leads to AR.
A combination of immunosuppressive agents is typically used chronically to pre-
vent AR, including a lymphocyte antagonist (usually a calcineurin inhibitor such as 
cyclosporine or tacrolimus) and an antiproliferative agent (such as azathioprine or 
mycophenolate mofetil), with or without corticosteroids. Antilymphocyte antibody 
therapy is often added during induction of immunosuppression or for treatment of 
“steroid-resistant” AR. The most common liver transplantation regimen consists of 
two doses of a monoclonal anti-IL2 receptor (basiliximab) as induction therapy and 
dual maintenance therapy with the CNI, tacrolimus, and the antimetabolite myco-
phenolate mofetil, which lessens the incidence and severity of rejection without 
increasing infection rates [100, 101].
AR remains an important clinical problem in liver transplantation. Incidence of 
AR ranges from 30 to 80%. Various risk factors for its development are known, such 
as low concentrations of immunosuppressants, prolonged cold ischemia time, and 
young receptor [102].
The diagnosis of AR in liver transplant recipients is normally suggested by fever 
and elevated levels of transaminases, bilirubin, or alkaline phosphatase. Among 
patients with T-tube drainage (which is increasingly uncommon), the biliary drain-
age may be seen to thicken, darken, and decrease in amount. The suspicion of AR 
mandates graft biopsy and studies to eliminate other possible causes of early hepatic 
graft failure as Doppler ultrasonography and, in some cases, cholangiography 
resonance. Biopsy findings are classified, according to a standardized set of criteria, 
as mild, moderate, and severe, with clear implications for prognosis. Microscopic 
observation reveals interstitial infiltrates of lymphocytes and macrophages, arte-
ritis, fibrinoid necrosis, and thrombosis. The involvement of the blood vessels is a 
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poor sign because its usual meaning is that of an episode of rejection that will be 
refractory to treatment. Biopsy may be relatively contraindicated due to coagulopa-
thy. In some circumstances transjugular biopsy offers a solution to this problem 
(Table 3) [100–102].
The differential diagnosis may be that of sepsis or problems with vascular 
integrity.
AR is normally treated with high-dose corticosteroids, but 5–10% of cases are 
steroid resistant; such recipients are then treated with an antilymphocyte antibody 
or tacrolimus at higher levels [100].
5. Primary graft liver dysfunction
Primary graft liver dysfunction is defined as the liver dysfunction that occurs 
from the moment of liver transplantation, which is not explained by the existence 
of another etiology, neither vascular nor bile.
Although there is improvement on preservation solutions and surgical tech-
niques [103], its incidence varies from 2 to 23% in several studies. It also seems to be 
the cause of 20–30% of the retransplants. The mortality without it is close to 80%.
The clinical suspect is established during the first hours after the liver transplant 
due to the presence of hemodynamic instability, metabolic acidosis, severe coagu-
lopathy (prothrombin time >20 seconds), hypertransaminasemia (>1000 U/l), and 
encephalopathy.
When primary dysfunction does not threaten patient life immediately, it is 
known as “poor early graft function.” On those several cases whose patient dies if 
the transplantation is not done, it is known as “primary graft failure” [104].
The pathogenesis of primary graft liver dysfunction is nearly related to the 
ischemia-reperfusion injury, so there are some predisposing donor factors that 
impact on recipient outcome [105, 106]. Prophylaxis includes a thorough donor 
selection and an exhaustive ischemia time control [107–109].
These premises are very important because of the fact that retransplantation is 
the isolated efficacy treatment.
Diagnosis is encouraged by additional examinations which discard secondary 
graft dysfunction. Transhepatic cholangiography must demonstrate a perme-
able bile duct as Doppler ultrasound and arteriography must demonstrate the 
absence of vascular complications. Liver biopsy is useful to discard a hyperacute 
rejection [104].
Nowadays the shortage of available donor organs is the major limiting fac-
tor in liver transplantation. Optimal deceased donors are generally young, 
previously healthy persons who develop a fatal brain injury due to causes such 
as head trauma, intracerebral hemorrhage, or anoxia. The relative paucity of 
donor organs has led transplant centers to consider organs from marginal donors 
(Table 4) [109–113].
Aside from the marginal donors, there are other factors associated with graft 
failure (Table 5) [113].
5.1 Treatment
As we have commented, the isolated efficacy treatment is retransplant and goes 
on identifying donors and recipient factors that lead to this kind of injury as avoid-
ing large ischemic times. The proper donor maintenance at the intensive care unit is 
at most important [103, 107, 108].

















Comment Characteristics Liver biopsy Differential diagnosis Treatment options
Hyperacute 
rejection
Rare in OLT 1–10 days 
posttransplant









Rarely: OKT3, cyclophosphamide, 
plasmapheresis
Acute rejection 30–70% occurs at mean of 
7–9 days
Often clinically silent apart from fever 
and RUQ pain
High AST and bilirubin









Methylprednisolone 1 g daily for 3 days
Table 3. 
AST, aspartate aminotransferase; MMF, mycophenolate mofetil; OLT, orthotopic liver transplantation; RUQ , right upper quadrant.
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6. Early infection in liver transplantation
Despite advances in liver transplantation, morbidity and mortality due to 
infectious complications remain the biggest problem [114, 115]. In many centers, 
infection is the leading cause of death after liver transplantation, particularly after 
the first year [116].. In series of autopsies, it has been announced that the infection 
was the cause of death in 64% of the 321 patients studied who died between 1982 
and 1997 [117]. Recent advances include in standardized and condoned protocols 
molecular research of viruses, demonstrating the binding between genetic poly-
morphisms of the immune response and the risk for specific infections and treat-
ment with new antibiotics, including the latest advances in C virus therapy [118].
The most common infections are bacterial (48%), followed by fungal (22%) and 
viral (12%). Some series observe an incidence of up to 1–2.5 episodes of infection 
per patient [119–121], this being the most common cause of fever in liver transplant 
recipients [122].
It is important to recognize a number of general principles [118, 123]:
1. Signs and symptoms of infection are attenuated by immunosuppression; 
therefore, the infection may be more difficult to diagnose.
2. Noninfectious causes of fever, such as rejection, medications, etc., can simulate 
an infection.
3. The variety of possible pathogens is extensive but is influenced by the timing 
of the infection in relation to transplantation.
4. Antibiotics have interactions with immunosuppressive medication.
5. The infection may be more severe and progress faster than an immunocompe-
tent host.
Marginal liver graft outcomes
• Donor age > 70 years
• Hepatitis C-positive donors
• Cold ischemia time > 12 hours
• Donations after cardiac death donors
• More than 30% steatosis
• Liver splits between two recipients
Table 4. 
Marginal liver graft outcomes.
Donor factors Recipient factors
• Hepatitis B core antibody positivity
• A mean arterial pressure lower than 60 mmHg more than 
20 minutes after life support withdrawal (after cardiac death)
• Hepatitis C virus infection
• Presence of malignancy




Donor and recipient factors.
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6. The risks of infection are determined by the balance between factors related 
to immunosuppressive treatment at full dose (dose, type, and duration of 
immunosuppressive therapy) and the existence of catheters, nutritional status, 
condition function of grafting, and the presence of underlying diseases.
Identifying risk factors before transplantation optimizes strategies to prevent 
infections. Although our ability to predict the risk of infection after transplantation 
remains limited, there are risk factors that can be modified, such as cytomegalovi-
rus (CMV) positivity and donor and receiver.
An important risk factor is the presence of a latent or unrecognized infection 
either from the donor or recipient. These infections can be reactivated and cause 
morbidity after the introduction of immunosuppressants. Therefore, both donors 
and recipients are routinely tested for infections such as CMV, other herpes viruses, 
tuberculosis, hepatitis B and C, syphilis, and human immunodeficiency virus.
Colonization of transplant recipients with organisms, such as methicillin-resis-
tant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE), 
can lead to infection posttransplant of these organisms. A significant prevalence of 
multiresistant gram-negative bacilli, such as expanded betalactase enterobacteria 
(BLEES) and Escherichia coli and carbapenem-resistant Klebsiella pneumoniae, has 
been observed in both the general population and solid organ transplant recipients, as 
they present risk factors for acquiring multi-resistant bacteria such as previous antibi-
otic therapy, catheter presence, exposure to the hospital environment, and presence of 
underlying diseases [124].
Other risk factors have been described, for example, those related to surgical 
complications. In a series of 101 patients, the risk factors associated with these 
infections were prolonged surgery of more than 12 hours and reoperation.
Among those related to pretransplantation were predictive infection, a serum 
value of alanine aminotransferase above 60 IU/L for all types of infections, and a 
T-helper ratio of 2.8, for fungal and viral infections [125].
Bacterial infections are seen more in those Roux-type y-procedures than with 
cholecystectomy, when there were multiple abdominal surgeries or there was a 
concomitant CMV infection in the postoperative period [126]. Graft dysfunction 
and the presence of critical pre-surgery diseases also confer an increased risk to 
acquire posttransplant infections.
The presence of CMV infection increases the risk of other infections, partly due 
to the immunomodulatory effects of this virus. Likewise, those who have rejection 
or those who have poor graft function after implantation increase the risk because 
they receive a more aggressive regimen of immunosuppressants.
The risk and type of infection found differ from the elapsed time after the 
implant and can be grouped into three major periods: first month, 1–6 months, and 
after 6 months.
Focusing on the first period or early infections, these are similar to those seen 
by an immunocompetent patient after surgery. Bacterial infections of nosocomial 
origin predominate, such as catheter infection, external drainage, or are related to 
foreign bodies, presence of necrotic tissue, or prolonged tracheal intubation [127]. 
We must also consider donor transmitted infections when there is an unexplained 
syndrome consistent with the infection.
Abdominal and lung infection are the most common, both associated with the 
presence of bacteremias [115].
Abdominal abscess and peritoneal abscess are the result of postoperative compli-
cations including gallbladder or surgical hematomas, with the predominant patho-
gens being enteric organisms [119]. Intrahepatic abscess and bile duct ischemia 
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manifest as a consequence of hepatic artery thrombosis, occurring in the immediate 
postoperative period. And cholangitis is caused by blockage of the bile tract, includ-
ing blockage of the Kher tube. Abdominal wall infections are also common.
Regarding lung infections, they are common in those who require intubations 
with prolonged mechanical ventilation. Pseudomonas aeruginosa and Enterobacter 
are most commonly grown. Other common bacteria include S. aureus, K. pneumoniae, 
Stenotrophomonas maltophilia, and Citrobacter freundii [119].
Colitis related with Clostridium difficile can occur in early periods, especially 
herethat have prolonged hospitalization. More than half of cases occur in the first 
posttransplant month. In fact, liver transplantation is identified as a risk factor 
for acquiring a C. difficile infection at the hospital due to immunosuppression and 
antibiotic treatment among other factors [128, 129].
Candida species are common pathogens identified in the first month. 
Bacteremia, surgical wounds, as well as urinary tract infection are common 
places of primary infection and can be subsequently disseminated [130]. The 
presence of esophagitis, oral cavity infection, and folliculitis is usually common. 
Due to the high mortality in candidemias, these should be treated aggressively, 
having to take into account the high incidence of Candida albicans reported in 
recent years.
Except for herpes simplex virus (HSV), viral infections are uncommon in the 
first month after transplantation. Without adequate prophylaxis, HSV reaction 
reaches up to 50%, in those HIV-positive patients prior to transplantation, usually 
manifesting as oral or genital ulcers.
7. Extrahepatic complications after liver transplantation
Patients undergoing a liver transplant may have long-term complications in 
different devices and systems. The most common are infections, de novo tumors, 
cardiovascular disease (including high blood pressure, hyperlipidemia, obesity, and 
metabolic syndrome), kidney disease, and diabetes.
These complications usually have a more or less direct relationship with the 
need for immunosuppressive drugs after implantation to prevent rejection of 
the implant. The use of high doses of corticosteroids for a long period promotes 
the onset of diabetes and increases the risk of cardiovascular disease, while the 
rest of immunosuppressants are associated with more common long-term com-
plications, the appearance of tumors, cardiovascular disease, and kidney failure.
The management of these pathologies does not differ from that received by 
patients not undergoing a transplant, so they can be detected and treated by differ-
ent specialists, having direct communication with the hepatologists for the adjust-
ment of medication in the different complications.
Next, we will further develop each of them.
7.1 De novo tumors
The incidence of de novo tumors is three times higher in liver transplant recipi-
ents than the rest of the population, making the first or second leading cause of 
long-term death in the liver implant patient (frequency varies according to the 
different series) [131].
The most commonly developed tumor is the skin epithelioma, directly related to 
sun exposure. Other de novo tumors associated with prolonged immunosuppressive 
treatment in liver transplants include non-Hodgkin lymphoma, Kaposi lymphoma, 
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and oropharyngeal, bladder, cervix, and lung cancers, 10–20% at 10 years of 
transplantation.
However, the incidence of breast, prostate, or colon tumors has not been 
increased with respect to the incidence in the general population, except if the eti-
ology of transplantation has been led to primary sclerosing cholangitis associated 
with ulcerative colitis, in which case the incidence of colon neoplasm increases.
The flattering factors do not differ from the rest of the population, but we must 
make special impact on primary and secondary prevention in this type of patients, 
given the situation of immunosuppression. That is why we must make special focus 
on the prevention of smoking habit, safe sex, and, of course, alcohol withdrawal.
7.2 Cardiovascular disease
Liver transplant recipients have a frequency three times higher than the general 
population suffering from a major cardiovascular event, considering in this group 
coronary heart disease, heart failure, sudden death, vascular brain accident, or severe 
occlusive peripheral artery disease. So the likelihood of suffering a cardiovascular 
event increases over the years, being 5% in the first 2 years posttransplant, 15% 
at 10 years after transplantation, and greater than 20% more than 10 years post-
transplant. It is considered to be the second or first cause of death in liver transplants 
according to the different series. This increase in incidence, in addition to immunosup-
pressive treatment, has been associated with increased cardiovascular risk factors over 
time, especially metabolic syndrome (HTA, obesity, and dyslipidemia) and diabetes.
Other habits that contribute to the development of cardiovascular disease are 
smoking and alcohol intake [130].
7.3 Metabolic syndrome
It is defined by the onset of diabetes, dyslipidemias, obesity, and HTA. Up to 
50–60% of patients undergoing HT will develop metabolic syndrome [132].
7.3.1 HTA
The incidence of HTA in liver transplant patients is related, in particular, to the 
vasoconstrictor effect of calcineurin inhibitors and to the mineralocorticoid effect 
of corticosteroids. It usually occurs in 40–60% of patients in the late period of liver 
transplantation.
We consider optimal voltage figures between 130 and 80 mmHg of systolic and 
diastolic blood pressure, respectively, being a little more restrictive than with the 
limits set for the general population (140 and 90 mmHg), adopting the same estab-
lished limits as for diabetic patients with renal impairment. We must be restrictive in 
terms of these figures, always maintaining lower levels in liver transplant patients.
We should avoid drugs such as NSAIDs as soon as possible, as in patients treated 
with calcineurin inhibitors tend to increase blood pressure levels.
Patients treated with calcineurin inhibitors should receive their antihypertensive 
treatment late in the afternoon or evening, as these drugs have a nightly blood pres-
sure rhythm, and therefore most of them we found at night. If, however, we cannot 
decrease tension levels, one might consider reducing the dose of these immunosup-
pressants [133, 134].
7.3.2 Obesity
Approximately 30% of TH receptors will develop obesity (BMI greater than 
30). This is due to the increase in sedentariness due to the situation of pretransplant 
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disease, the corticoid treatment, the release of restrictive diets once transplanted, 
and the decrease of physical exercise. The treatment is the same as in any non-
immunocompromised patient: physical exercise and low-calorie diets. If necessary, 
lipase inhibitors could be administered as adjuvant drugs in weight loss; in which 
case, it would be necessary to monitor immunosuppressant levels more thoroughly 
to prevent possible interactions that decrease their absorption [132].
7.3.3 Dyslipidemias
The administration of immunosuppressants such as calcineurin inhibitors, 
mTOR inhibitors, and corticosteroids, independently or in addition to each 
patient’s genetic predisposition, may contribute to rising levels of plasma cho-
lesterol and triglycerides, with increased LDL and decreased HDL, resulting in 
hypercholesterolemia and hypertriglyceridemia in up to 40% liver transplant 
recipients. The treatment is using hypolipidizing drugs (statins and fibrates) 
and diet, as in the rest of the population. Keep in mind that patients who take 
cyclosporine and need treatment with statin are at higher risk of developing severe 
myopathy [132].
7.3.4 Diabetes
It has an incidence between 20 and 35% development in transplant patients. 
Factors that contribute to its emergence are advanced age, obesity, existing 
pretransplant diabetes, immunosuppressants with diabetic effects, especially 
tacrolimus, the development of insulin resistance of corticosteroids, and the insulin 
secretion deficit of calcineurin inhibitors.
Treatment is based on insulin and oral antidiabetics, although most patients 
with HT will need insulin because of the lower efficacy of ADOs, with the highest 
insulin needs being in the morning and noon in those patients with corticosteroids, 
since the pattern is usually in the morning [132].
7.4 Chronic renal failure
The incidence of renal impairment in liver transplant patients is 50–70% higher 
[135]. The most directly related cause is treatment with calcineurin inhibitors, due 
to its nephrotoxic effect, although factors such as HTA, diabetes, or other infec-
tions that secondarily affect the correct kidney filtration, such as HCV infection, 
may also contribute. Of these patients treated with calcineurin inhibitors, 10% will 
develop a chronic end-stage renal disease (glomerular filter age less than 30 ml/
min/1.73 m2), in need of hemodialysis therapy or even renal transplantation in 
1–2% of cases. This percentage, fortunately, has been declining in recent years 
coinciding with the lower use of this family of immunosuppressants. Clearly, 
for patients who develop renal impairment, we must readjust immunosuppres-
sive treatment, reducing the dose of calcineurin inhibitors or substitutes or other 
non-nephrotoxic immunosuppressants such as inhibitors mTOR or mycophenolate. 
Similarly, the use of nonsteroidal anti-inflammatory drugs and all drugs that may 
contribute to worsening kidney function will be avoided [135].
7.5 Other complications
Apart from the most important complications in both frequency and clinical 
impact, liver transplant recipients may develop other types of related complications 
in whole or in total or with the intake of immunosuppressive drugs. In this way, 
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patients taking calcineurin inhibitors may develop neurological problems, espe-
cially headache, migraine, insomnia tremor, and paresthesia.
Corticoids: Ostearticular pathology, especially osteoporosis (50%), Cushingoid 
facies, alteration in body fat distribution, hirsutism.
Mycophenolate: diarrhea and vomiting, especially with mofetil mycophenolate, 
less common with sodium mycophenolate, bone marrow depression also favored by 
concomitant administration of interferon for any other reason.
mTOR inhibitors: bone marrow depression, respiratory problems such as 
pulmonary fibrosis and organizational pneumonia, difficulty healing wounds.
And all of them can lead to more or less sexual dysfunction.
So it is necessary to do a complete scan and anamnesis to be able to detect these 
side effects and assess modification of pattern or replacement of it [133, 134].
7.6 Survival
Annual mortality after the first year after liver transplantation is 2–3% per year, 
higher than in the general population of the same age and gender. The principal 
causes of death are cardiovascular diseases, appearance of novo tumors, and relapse 
of hepatitis C [136–139].
The quality of life posttransplantation is not fully satisfactory although it is 
better than the quality of pretransplant life. Only a percentage of lower patients 
presents a quality of life lower than the general population, about everything in 
aspects related with the function staff on paper partner-work family.
8. Conclusions
LT is nowadays a common surgical technique in many hospitals and is undoubt-
edly the most definitive treatment for end-stage liver disease. Early monitoring and 
a correct treatment of this kind of patients at the ICU are of utmost importance. 
The success lies in early detection and treating of complications by using the proper 
diagnostic and medical or surgical techniques that all intensivists need to know and 
manage. All the surgical and medical team need to deploy their best competencies 
to save the graft and the patient’s life.
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